soma online description chemistry ingredients blackbox

teen tramadol addiction

Associated cardiovascular risk factors include age over 70 years, hypertension, diabetes, prior cerebrovascular accident, left atrial diameter greater than or equal to 50 mm or left ventricular ejection fraction [LVEF] <40%. The ATHENA trial, which involved 4,628 patients with AF or AFL and more than 2,300 patients receiving Multaq on top of standard therapy, demonstrated a 24% reduction in time to first CV hospitalization or all-cause mortality (P<0. Patients were predominantly NYHA II and III (New York Heart Association classification) and only 25% had a history of AF/AFL at randomization.S. soma online description chemistry ingredients blackbox Sanofi-aventis is listed in Paris and in New York . soma online description chemistry ingredients blackbox Multaq is an anti-arrhythmic indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted.sanofi-aventis. tramadol lethal level

The efficacy and safety of Multaq 400 mg twice daily was evaluated in five controlled studies, ATHENA, ANDROMEDA, EURIDIS, ADONIS, and DAFNE, involving nearly 6,300 patients including more than 3200 patients who received Multaq.027]. Multaq should not be given to patients who are or may become pregnant (Category X) or nursing. soma online description chemistry ingredients blackbox S. soma online description chemistry ingredients blackbox " Multaq is to be given twice daily as a 400 mg tablet and should be taken as one tablet with the morning and evening meals. makers of prescription vicodin

"Sanofi-aventis is proud of its ability to bring innovative therapies to market and contribute to reducing the public health burden of atrial fibrillation. Initiation of Multaq treatment is contraindicated in patients with severe heart failure (NYHA class IV) or NYHA Class II - III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic. The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance. soma online description chemistry ingredients blackbox About dronedarone (Multaq) Multaq, discovered and developed by sanofi-aventis, is one of the major therapeutic innovations in patients with atrial fibrillation in the last twenty years. soma online description chemistry ingredients blackbox This unstable population corresponds to the population of the ANDROMEDA trial in which patients receiving dronedarone had a greater than 2-fold increase in mortality compared to placebo. In a placebo-controlled study in patients with severe heart failure requiring recent hospitalization or referral to a specialized heart failure clinic for worsening symptoms (the ANDROMEDA study), patients given dronedarone had a greater than two-fold increase in mortality.